ABBVIE INC.
Ownership & governance
Executives 5Directors 10Avg age 63Avg tenure 8.7y
RM
Robert Michael
Chief Executive Officer
Age 55Since 2024-06-30Profile →
+14
Executives5
RM
Robert Michael→
Chief Executive Officer
Age 55Since 2024-06-30
SR
Scott Reents
Director of Finance/CFO
Age 59Since 2022-06-22
LR
Linda Ray
Chief Tech/Sci/R&D Officer
—Since 2024-02-29
LA
Latif Akintade
Chief Tech/Sci/R&D Officer
—Since 2023-05-31
RT
Roopal Thakkar
Chief Tech/Sci/R&D Officer
Age 54Since 2002-12-31
Board of directors10
RA
Roxanne Austin→
Director/Board Member
Age 65Since 2012-12-31
WB
William Burnside→
Director/Board Member
Age 74Since 2012-12-31
ER
Edward Rapp→
Director/Board Member
Age 68Since 2012-12-31
RM
Robert Michael→
Chairman
Age 55Since 2025-06-30
RR
Rebecca Roberts→
Director/Board Member
Age 73Since 2017-12-31
TF
Thomas Freyman→
Director/Board Member
Age 71Since 2020-05-07
BH
Brett Hart→
Director/Board Member
Age 57Since 2015-12-31
MM
Melody Meyer→
Director/Board Member
Age 68Since 2016-12-31
Shareholders4
| Name | Stake | Shares |
|---|---|---|
| Vanguard Capital Management LLC | 6.502 % | 114,880,324 |
| BlackRock Advisors LLC | 6.391 % | 112,913,460 |
| STATE STREET CORPORATION | 4.597 % | 81,217,516 |
| JPMorgan Investment Management, Inc. | 3.212 % | 56,741,691 |
Catalog · 2026-07-09
Registry officers12
| Name | Role | Since | Shares |
|---|---|---|---|
| Robert Michael | Chairman | 2025-06-30 | - |
| Brett Hart | Director/Board Member | 2015-12-31 | - |
| Edward Rapp | Director/Board Member | 2012-12-31 | - |
| Frederick Waddell | Director/Board Member | 2012-12-31 | - |
| Jennifer Davis | Director/Board Member | 2023-10-10 | - |
| Melody Meyer | Director/Board Member | 2016-12-31 | - |
| Rebecca Roberts | Director/Board Member | 2017-12-31 | - |
| Roxanne Austin | Director/Board Member | 2012-12-31 | - |
Registry · as of 2026-07-09
Group companies
| Name | Category |
|---|---|
| AbbVie Biopharmaceuticals GmbH Taiwan Branch | Pharmaceuticals: Major |
| Allergan Pharmaceuticals Ireland ULC | Pharmaceuticals: Major |
| Allergan Pharmaceuticals Ireland ULC | Pharmaceuticals: Major |
| Aptalis Pharma Canada ULC | Pharmaceuticals: Major |
| Aptalis Pharma Canada ULC | Pharmaceuticals: Major |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 282.61Range 200–328Analysts 28
200Mean 282.61328
- Strong buy 8
- Buy 16
- Hold 5
- Strong sell 1
Broker actions40 of 420
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| RBC Capital | Reiterated | Outperform | 280 | 2026-10-13 |
| UBS | Maintained | Neutral | 275 | 2026-10-09 |
| Guggenheim | Reiterated | Buy | 288 | 2026-10-09 |
| JP Morgan | Maintained | Overweight | 300 | 2026-10-08 |
| Cantor Fitzgerald | Maintained | Overweight | 290 | 2026-10-08 |
| Morgan Stanley | Maintained | Overweight | 310 | 2026-10-07 |
| Scotiabank | Maintained | Sector Outperform | 320 | 2026-10-06 |
| HSBC | Maintained | Buy | 315 | 2026-09-10 |
| Piper Sandler | Maintained | Overweight | 303 | 2026-08-20 |
| Wells Fargo | Maintained | Overweight | 300 | 2026-08-17 |
| Wolfe Research | Upgrade | Outperform | 300 | 2026-08-13 |
| BNP Paribas | Maintained | Neutral | 247 | 2026-08-11 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.